Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects

類似資料

• Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function
  著者:: Shoaf, Susan E, 等
  出版事項: (2014)
• Integrated pharmacokinetics and pharmacodynamics of epoprostenol in healthy subjects
  著者:: Nicolas, Laurent B, 等
  出版事項: (2012)
• Pharmacokinetics and pharmacodynamics of γ‐hydroxybutyrate in healthy subjects
  著者:: Liechti, Matthias E., 等
  出版事項: (2016)
• Safety, pharmacokinetics and pharmacodynamics of GLPG0974, a potent and selective FFA2 antagonist, in healthy male subjects
  著者:: Namour, Florence, 等
  出版事項: (2016)
• Pharmacokinetic–pharmacodynamic relationships of central nervous system effects of scopolamine in healthy subjects
  著者:: Liem-Moolenaar, Marieke, 等
  出版事項: (2011)